#USA #Washington #Nereus #Vanda Pharmaceuticals #GLP-1 Therapy

Vanda Pharmaceuticals Reports Positive Findings in Study 3601 for NEREUS™

Vanda Pharmaceuticals, Inc. has recently unveiled promising results from Study 3601, a Phase III randomized, placebo-controlled trial evaluating NEREUS™ (tradipitant). This investigational drug is an oral neurokinin-1 (NK-1) receptor antagonist designed to prevent vomiting associated with GLP-1 receptor agonist therapy. GLP-1 medications are widely used for managing conditions such as obesity and diabetes. However, nausea and vomiting are common side effects that can lead to treatment discontinuation among patients.

Key Outcomes of Study 3601

The study's primary endpoint focused on the occurrence of vomiting, wherein NEREUS™ demonstrated a significant reduction in overall episodes. Specifically, the results showed:

• - Any vomiting occurred in 43.0% of participants taking NEREUS™ compared to 58.5% among those assigned to placebo, representing a relative reduction of 27% (p=0.006).
• - When examining severe nausea in conjunction with vomiting, 33.1% of NEREUS™ participants experienced these symptoms, versus 50.6% in the placebo group, marking a 35% relative reduction (p=0.002).
• - Furthermore, frequent multi-day vomiting was reduced by 60% and extreme vomiting reductions reached an impressive 81%, suggesting a substantial improvement in patient tolerance for GLP-1 therapies.

Study Design and Dosing

In the study, participants received a single high-dose (1 mg) of semaglutide—a potent GLP-1 receptor agonist—without the gradual dose titration typically observed in clinical settings. This design aimed to create a rigorous testing environment to evaluate NEREUS™’s effectiveness under more extreme conditions of emesis.

A pooled analysis from both Phase II and Phase III studies confirmed that NEREUS™ consistently reduced the probability of vomiting across various concentrations of semaglutide, indicating that this treatment could be applicable in real-world dosing scenarios as well.

Mechanism of Action

NEREUS™ works by antagonizing NK-1 receptors located in the central nervous system, particularly in areas known to trigger the vomiting reflex. By interfering with the substance P signaling pathway, NEREUS™ offers a robust approach to mitigating symptoms associated with nausea and vomiting triggered by multiple GLP-1 therapies.

The Broader Context

Research indicates that nausea and vomiting are significant barriers to the effective use of GLP-1 receptor agonists, with around half of the patients discontinuing treatment within a year primarily due to gastrointestinal adverse effects. As the global market for GLP-1 therapeutics is projected to exceed $50 billion, enhancing the tolerability of these medications could significantly impact patient adherence and treatment success.

Future Steps for Vanda Pharmaceuticals

Encouraged by the study results, Vanda plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the findings and to prepare a supplemental New Drug Application (sNDA) for approval of NEREUS™ for this indication. The safety profile of NEREUS™, observed in previous trials, remained consistent throughout the study, with no new safety concerns identified.

Dr. Mihael H. Polymeropoulos, President and CEO of Vanda Pharmaceuticals, expressed optimism, stating, "These results demonstrate that NEREUS can meaningfully reduce vomiting and frequent multi-day vomiting induced by GLP-1 therapy, which are key contributors to treatment discontinuation."

As Vanda Pharmaceuticals continues its commitment to addressing unmet medical needs, the success of NEREUS™ could potentially offer significant benefits to countless patients navigating the complexities of GLP-1 therapy. The future holds promising opportunities as they await regulatory discussions and possible market introduction.

Conclusion

The encouraging results from Study 3601 represent a vital advancement in improving the patient experience associated with GLP-1 therapies. By potentially alleviating one of the most distressing side effects of this treatment, NEREUS™ could play a crucial role in helping patients adhere to their medication regimens and achieve better health outcomes.